NCI SBIR Contract for Patient Navigation Tool Prototype Development
NCT04892927 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25
Last updated 2021-05-19
Summary
GMG ArcData will create a mobile-based application to improve communications and data exchange among patients and navigators involved in new pancreas surgery oncology episodes of care. Functionality will align with care processes using smartphone and the EHR patient portal. GMG will apply user-centered design theory and behavioral psychology approaches to co-design, develop, and test usability of features that optimize patient navigators-patient encounters on scheduling issues, nutrition guidance, pain management, wellbeing assessments, and activity tracking. Evaluation endpoints will reflect how the application improves the efficiency of workflows and lessens cognitive burden. Study will assess how patients and navigators perceive the tool's ability to provide more control and easier access to information about surgical care. The key project innovations are based on Fast Healthcare Interoperability Resources (FHIR)-based engineering standards that enable interoperability among digital health platforms, apply 'recommender' functions based on similar patients' experiences, and exploit microeducation tools to enhance patient understanding about their surgical care. The research team has partnered with MedStar Health and Georgetown University Lombardi Comprehensive Cancer Center to co-design the software and access patients for usability testing. Successful implementation will lead to exploring a joint venture for scaling to other care episodes, expanded functionality, and co-creating business models for commercialization.
Conditions
- Pancreas Cancer
- Hepatobiliary Cancer
- Patient Engagement
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Georgetown University
collaborator OTHER -
GMG Arcdata LLC
lead INDUSTRY
Principal Investigators
-
Gregory Downing · GMG Arcdata LLC
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-03
- Primary Completion
- 2021-05-26
- Completion
- 2021-06-30
Countries
- United States
Study Locations
More Related Trials
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer
NCT02707315 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Project Survival-Prospective Biomarker Discovery
NCT02781012 ·Status: UNKNOWN
-
A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2)
NCT07336953 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
NCT05621824 ·Status: NOT_YET_RECRUITING
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
NCT02361320 ·Status: RECRUITING ·Phase: NA
-
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT03484299 ·Status: RECRUITING ·Phase: PHASE1
-
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT02754726 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
NCT07326137 ·Status: RECRUITING
-
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
NCT06937996 ·Status: RECRUITING
-
Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife
NCT02716207 ·Status: COMPLETED ·Phase: NA
-
Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients
NCT02866383 ·Status: COMPLETED ·Phase: PHASE2
-
RNA Precision Oncology in Advanced Pancreatic Cancer
NCT04476537 ·Status: TERMINATED ·Phase: NA
-
NGS and TME for Evidence-based Treatment of Pancreatic Cancer
NCT02767700 ·Status: COMPLETED
-
Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers
NCT02683824 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
NCT03334708 ·Status: RECRUITING
-
Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer
NCT01458717 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
NCT03498326 ·Status: RECRUITING ·Phase: PHASE2
-
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
NCT02648282 ·Status: COMPLETED ·Phase: PHASE2
-
Innovative Therapeutic Treatments to Inhibit Perineural Invasion in Pancreatic Adenocarcinoma
NCT06616688 ·Status: NOT_YET_RECRUITING
-
Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
NCT02929797 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT06151223 ·Status: RECRUITING
-
A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer
NCT01986738 ·Status: COMPLETED
-
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
NCT02481635 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
NCT00005926 ·Status: COMPLETED ·Phase: PHASE2